Voyager Therapeutics Inc C.VYGR

Primary Symbol: VYGR

Healthcare Biotechnology

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

NDAQ:VYGR - Post by User

Voyager Therapeutics Inc > Voyager Doubles AUN in a single month

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Dec 29, 2020 10:32am

240 Views

Post# 32190896

RE:Voyager Doubles AUN in a single month

Based on today's NR, the monthly rate of AUM gains is about $55 million.
That means an excellent chance of exiting 2021 above $1 billion in AUM.

That would suggest valuations above $25 at some point in this growth cycle to $1 billion..

<< Previous

Bullboard Posts

Next >>

SSR Mining reviews deadly landslide, faces class-action lawsuits